News
Every week we scan the studies, regulators and headlines for our tracked compounds, then keep only the genuine movements. New trials, approvals, safety flags — not celebrity gossip or stock tips.
Six cases of acute liver toxicity linked to unapproved peptide products labeled Retatrutide in Victoria. Government warning issued. Contamination suspected.
Why it matters: Real adverse events tied to unregulated supply—this is why oversight matters.
Read the source · news36live →American Medical Association House of Delegates passed a resolution demanding the FDA do better at regulating unproven peptides. No names named, but sends a signal.
Why it matters: Organized medicine is sounding an alarm about the Wild West peptide market.
Read the source · news36live →Since January 2026, six cases of acute liver toxicity linked to unapproved Retatrutide products in Australia. A contaminant is suspected.
Why it matters: Repeated safety signal (same as [5])—real people, real harm, unregulated supply chain to blame.
Read the source · news36live →Drug Topics reports the FDA is evaluating several peptides, including KPV, for inclusion on the official compounding substances list. This is a meaningful regulatory step affecting what pharmacists can legally compound.
Why it matters: Compounding list status would legitimize certain peptides in clinical settings.
Read the source · Drug Topics →Mail & Guardian reports Retatrutide is being sold illegally in South Africa outside regulatory oversight. This signals a real safety and enforcement issue in a major region.
Why it matters: Illegal supply chains mean zero quality control or provenance verification.
Read the source · Mail & Guardian →Reuters reports FDA staff raised safety concerns about KPV-backed compounds before a high-profile advisory panel meeting. Institutional skepticism on a politically salient peptide.
Why it matters: Shows FDA independence in questioning compounds backed by prominent figures.
Read the source · Reuters →MedPage Today reports FDA staff raised questions about TB-500, KPV, and other peptides ahead of an advisory committee review. Signals formal regulatory scrutiny of safety profiles.
Why it matters: FDA internal concerns could shape future approval or restriction decisions.
Read the source · MedPage Today →Get the week's peptide news in one email.
Every Friday. Genuine movements only — and an honest “quiet week” when there's nothing worth your time.